微粒-经导管动脉化疗栓塞治疗肝细胞癌外周血程序性死亡受体1表达及临床意义初探

肝癌电子杂志 ›› 2023, Vol. 10 ›› Issue (3): 48-51.

微粒-经导管动脉化疗栓塞治疗肝细胞癌外周血程序性死亡受体1表达及临床意义初探

任志忠¹, 岳元勋², 汪桠琴¹, 王雅静¹, 张跃伟^1,*

1.北京清华长庚医院肝胆胰中心肝胆介入科,北京 102218;
2.首都医科大学附属北京潞河医院疼痛科,北京101149

收稿日期:2023-04-08 出版日期:2023-09-30 发布日期:2023-10-25
通讯作者: ^*张跃伟,E-mail:zhangyuewei1121@sina.com
基金资助:
清华大学精准医学科研计划（10001020103）; 首都卫生发展科研专项（首发2020-2-2242）

The expression and clinical significance of PD-1 in peripheral blood of hepatocellular carcinoma treated with m-TACE

Ren Zhizhong¹, Yue Yuanxun², Wang Yaqin¹, Wang Yajing¹, Zhang Yuewei^1,*

1. Department of Hepatobiliary Interventional, Hepatobiliary Pancreatic Center,Beijing Tsinghua Changgeng Hospital,Beijing 102218, China;
2. Department of Pain, Beijing Luhe Hospital Affiliated with Capital Medical University,Beijing 101149, China

Received:2023-04-08 Online:2023-09-30 Published:2023-10-25
Contact: ^*Zhang Yuewei,E-mail:zhangyuewei1121@sina.com

摘要/Abstract

摘要： 目的：初步探讨应用微粒-经肝动脉化疗栓塞（m-TACE）治疗肝细胞癌（HCC）术后外周血中CD4⁺程序性死亡受体1(PD-1)、CD8⁺PD-1的变化及意义。
方法：选取 2021—2022年北京清华长庚医院肝胆胰中心临床资料完整的20例有 m-TACE治疗指征的中晚期HCC患者（HCC组）,选择非酒精性肝硬化患者及健康志愿者各 12 例作为肝硬化组和健康组。应用流式细胞术检测健康组、肝硬化组和HCC患者m-TACE术前与术后1~2周外周血中CD4⁺PD-1、CD8⁺PD-1表达情况。
结果：HCC组外周血CD4⁺PD-1、CD8⁺PD-1表达均明显高于肝硬化组及健康组。HCC患者经m-TACE治疗后1~2周外周血CD4⁺PD-1表达由治疗前（38.65±8.56）%下降至（31.65±5.81）%（P<0.05）,同样CD8⁺PD-1表达也较治疗前下降[（41.17±12.12)% ∶(29.29±10.48）%,P<0.05]。m-TACE治疗后疗效好的患者术后外周血PD-1表达较低。
结论：m-TACE治疗HCC可能降低外周血CD4⁺/CD8⁺ PD-1的表达。

关键词: 肝细胞癌, 经导管动脉化疗栓塞, 程序性死亡受体1, 免疫治疗

Abstract: Objective:To explore the changes and significance of CD4⁺programmed death receptor 1(PD-1) and CD8⁺PD-1 in peripheral blood after hepatocellular carcinoma(HCC) patient streated with microparticles transcatheter arterial chemoembolization(m-TACE).
Method:From 2021 to 2022, 20 patients with intermediate and advanced HCC with indications for m-TACE treatment were selected from the Hepatobiliary and Pancreatic Center of Beijing Tsinghua Chang Gung Hospital (HCC group), and 12 patients with non-alcoholic cirrhosis and 12 healthy volunteers were selected as cirrhosis group and healthy group. Flow cytometry was used to detect the expression of CD4⁺PD-1 and CD8⁺PD-1 in peripheral blood of healthy, cirrhotic, and liver cancer patients before and 1-2 weeks after m-TACE.
Result:The expression of CD4⁺/CD8⁺PD-1 in peripheral blood of the HCC group was significantly higher than that of the liver cirrhosis group and the healthy group. After 1-2 weeks of m-TACE, the expression of CD4⁺/CD8⁺PD-1 of HCC patients decreased compared to before treatment(P<0.05). Patients with good therapeutic effects after m-TACE have lower expression of CD4⁺/CD8⁺PD-1 in peripheral blood(P<0.05).
Conclusion:m-TACE treatment for HCC can reduce the expression of CD4⁺/CD8⁺PD-1 in peripheral blood.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Programmed death receptor 1, Immunotherapy

任志忠, 岳元勋, 汪桠琴, 王雅静, 张跃伟. 微粒-经导管动脉化疗栓塞治疗肝细胞癌外周血程序性死亡受体1表达及临床意义初探[J]. 肝癌电子杂志, 2023, 10(3): 48-51.

Ren Zhizhong, Yue Yuanxun, Wang Yaqin, Wang Yajing, Zhang Yuewei. The expression and clinical significance of PD-1 in peripheral blood of hepatocellular carcinoma treated with m-TACE[J]. Electronic Journal of Liver Tumor, 2023, 10(3): 48-51.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021, 71(3):209-249.
[2] KULIK L, EL-SERAG H B. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 6(2):477-491.
[3] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国抗癌协会肝癌专业委员会,北京医学会外科学分会肝脏学组,等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021 版)[J/CD].肝癌电子杂志, 2021, 8(2):6-15.
[4] 张跃伟,刘影.明胶海绵微粒经导管肝动脉化学治疗栓塞术对原发性肝癌疗效分析[J].中华肝脏病杂志, 2013, 21(8):637-638.
[5] LEONE P, SOLIMANDO A G, FASANO R, et al.The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment[J]. Vaccines (Basel) , 2021, 9(5):532.
[6] LENCIONI R, LLOVET J M.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1):52-60.
[7] LIU Y, ZHANG YW, BAUTISTA D, et al.Transarterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-centre experience[J]. Cell Biochem Biophys, 2015, 71(1):99-104.
[8] REN Z Z, YUE Y X, ZHANG Y W, et al.Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles[J]. Front Immunol, 2021, 12:624789.
[9] YUE Y X, REN Z Z, LIU Y, et al.Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma[J]. J Interv Med, 2019, 2(1): 21-26.
[10] WU Y, LIN H, YOU X, et al.Immune checkpoint blockade in chinese patients with hepatocellular carcinoma: characteristics and particularity[J].Front Oncol, 2022, 12:764923.
[11] SORENSEN S F, ZHOU W, DOLLED-FILHART M, et al.PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy[J].Transl Oncol, 2016, 9(1): 64-69.
[12] 程小珍,李晓东,王顺兰,等.肝癌患者TACE 治疗前后外周血 PD-1、PD-L1 的表达及临床意义[J].中国现代医学杂志, 2019,29(3):33-37.
[13] MONTASSER A, BEAUFRÈRE A, CAUCHY F, et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma[J]. Histopathology, 2021, 79(1):36-46.

[1]	陈启晨, 陆荫英, 刘连新. 前瞻性临床研究中基于免疫检查点抑制剂治疗不可切除肝细胞癌的不良反应：系统综述和Meta分析[J]. 肝癌电子杂志, 2023, 10(3): 12-26.
[2]	缪伎玄, 靳勇. 肝细胞癌血管介入治疗联合靶向和免疫治疗进展[J]. 肝癌电子杂志, 2023, 10(3): 31-37.
[3]	赵莹, 黎可人, 杨艳美, 李微, 李广欣, 黎功. 放射治疗联合免疫检查点抑制剂及仑伐替尼治疗肝细胞癌合并门静脉癌栓的疗效分析[J]. 肝癌电子杂志, 2023, 10(3): 58-63.
[4]	王瑜, 童列杏, 康婉英, 丁鑫, 钱和生. 机器学习识别肝细胞癌骨转移驱动基因及体外放疗分析[J]. 肝癌电子杂志, 2023, 10(3): 64-75.
[5]	辛玲霞, 许新, 翟医蕊, 邓敏, 陈波. 肝细胞癌伴门静脉癌栓放射治疗进展[J]. 肝癌电子杂志, 2023, 10(3): 76-82.
[6]	潘文冰, 陆瑶, 李岩, 史卓林, 刘玉娣. 基于循证医学的叙事护理模式对原发性肝癌患者经导管动脉化疗栓塞术后早期离床活动和依从性的影响[J]. 肝癌电子杂志, 2023, 10(3): 89-92.
[7]	郎梦然, 王宏光, 蒙轩, 冯小龙, 王小雯, 赵建军. 肝尾状叶巨大肝细胞癌手术切除1例[J]. 肝癌电子杂志, 2023, 10(3): 93-96.
[8]	陈晓, 毛一雷, 邵国良. 仑伐替尼联合经导管动脉化疗栓塞术一线治疗晚期肝细胞癌：Ⅲ期随机临床试验（LAUNCH）[J]. 肝癌电子杂志, 2023, 10(2): 1-6.
[9]	张艺旋, 马亚锐, 王小兵, 焦宇辰. 转座酶可及性染色质测序法联合RNA测序探究解旋酶样转录因子基因的缺失对肝细胞癌的影响[J]. 肝癌电子杂志, 2023, 10(2): 7-15.
[10]	卞涛, 秦峰, 王胜杰, 王会, 韩山山. 微小RNA-551a参与晚期肝细胞癌患者索拉非尼应答机制研究[J]. 肝癌电子杂志, 2023, 10(2): 16-26.
[11]	张丽莎, 康明佳, 赵健. 肝细胞癌对仑伐替尼耐药机制的研究进展[J]. 肝癌电子杂志, 2023, 10(2): 37-40.
[12]	申亚琼, 李皎, 李兴欣, 徐敬, 金焰. 赖氨酰氧化酶样蛋白2在肝细胞癌发生发展中的作用研究进展[J]. 肝癌电子杂志, 2023, 10(2): 41-44.
[13]	赵海涛. 胆系肿瘤治疗之全程管理[J]. 肝癌电子杂志, 2023, 10(2): 59-61.
[14]	王雅宁, 盛基尧, 王赈霄, 张学文. 异常凝血酶原在肝细胞癌诊疗中的应用进展[J]. 肝癌电子杂志, 2023, 10(1): 39-44.
[15]	黄素明, 李倩, 纪元. 肝脏混合性肝细胞癌-神经内分泌癌综合治疗1例[J]. 肝癌电子杂志, 2023, 10(1): 49-52.